Lenalidomide Capsule
Product Images NDC 59651-342

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 59651-342). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Kaplan-meier Curves Of Progression-free Survival (Lenalidomide Fig1)

The text seems to be a table with information about different variables. The table shows data related to the Progression Free Survival among different experimental conditions (RdContinuous, RA18, and MPT). The table contains values for the number of subjects at risk and the mortality rate at different months of treatment, in addition to percentages of PFS evaluated in each experimental condition.*

FDA Label Image

Package Label-principal Display Panel (10 mg 7 (1 x 7) Unit-dose Capsules)

This text contains information for a prescription medication called Lenalidomide Capsules 10mg. It provides details about the contents of a single dose package and the manufacturer name and address. The medication guide for dosing and administration is also mentioned, along with a warning about potential birth defects. It is not clear what the initial two lines of text are referring to.*

FDA Label Image

Package Label-principal Display Panel (15 mg (100 Capsules Bottle))

This is a description of Lenalidomide Capsules, distributed by Aurobindo Pharma USA, Inc. Each capsule contains 15 mg of Lenalidomide, made in India. The prescribing information for dosing and administration can be found separately. A medication guide must be provided to each patient by the pharmacist. The capsules must be stored at a temperature range of 20° to 25°C (68° to 77°F) and could potentially cause birth defects. The text also includes a warning against printing the dotted lines.*

FDA Label Image

Package Label-principal Display Panel (15 mg 7 (1 x 7) Unit-dose Capsules)

FDA Label Image

Package Label-principal Display Panel (20 mg (100 Capsules Bottle))

This is a description of a medication called Lenalidomide. It comes in the form of 20mg capsules distributed by Aurobindo Pharma USA, Inc. The prescribing information should be consulted for dosing information. A Medication Guide should be dispensed to each patient along with the medication. The medication should be stored at 20-25°C. There is a warning about the potential for birth defects. The text also includes manufacturing information as well as a code.*

FDA Label Image

Package Label-principal Display Panel (20 mg 7 (1 x 7) Unit-dose Capsules)

This description is for a medication called Lenalidomide Capsules, produced by Aurobindo Pharma USA. The medication comes in a package of seven (1x7) unit-dose capsules and each capsule contains 20mg of lenalidomide. It is important to read the prescribing information for dosing and administration. The store temperature requirement for this medication is between 20° to 25° (68° to 7°F). The package is not child resistant. The text also includes a warning for potential human birth defects.*

FDA Label Image

Package Label-principal Display Panel (25 mg (100 Capsules Bottle))

FDA Label Image

Package Label-principal Display Panel (25 mg 7 (1 x 7) Unit-dose Capsules)

This is a prescription drug package for Lenalidomide Capsules. The package contains seven unit-dose capsules, each capsule containing 25mg of Lenalidomide. The prescribing information for the drug's dosing and administration are also mentioned. It also contains cautionary information about the potential for human birth defects. The package is distributed by Aurobindo Pharma USA, Inc, and made in India. The Over Printing Zone and UNVARNISH ZONE are also mentioned.*

FDA Label Image

Kaplan-meier Curves Of Overall Survival (Lenalidomide Fig2)

FDA Label Image

Kaplan-meier Estimate Of Time To Progression (MM Study 1)

The text represents a chart showing the proportion of subjects and time to progression in months for two groups (Lenalidomide/Dex and Placebo/Dex). The chart also shows a comparison of Hazard Ratio between the groups along with the Log Rank p value.*

FDA Label Image

Kaplan-meier Estimate Of Time To Progression (MM Study 2)

This is a graph that shows the results of a clinical trial that compared the effectiveness of lenalidomide/dex vs placebo/dex in delaying the progression of the disease. The x-axis represents the time to progression in months, while the y-axis represents the proportion of subjects who did not progress in the study. The results show that the treatment with lenalidomide/dex was significantly more effective than the placebo/dex, with a hazard ratio (HR) of 0.324 (95% confidence interval: 0.240 to 0.438) and a p-value of <0.001 according to the log-rank test.*

FDA Label Image

Package Label-principal Display Panel (2.5 mg Container Label (30 Capsules Bottle))

FDA Label Image

Package Label-principal Display Panel (2.5 mg Blister Carton (1 x 7 Unit-dose Capsules))

This is a description of a medication called Lenalidomide 2.5mg contained in a capsule. The packaging has a warning regarding the potential for human birth defects and indicates that the medication guide provided separately should be given to each patient. The capsules are distributed by Aurobindo Pharma USA, Inc. and should be stored at 20° to 25°C. There are 7 unit-dose capsules in each package. There is also information about the over printing zone and the unvarnished zone. Code: TS/DRUGS/24/2015. NDC 59651-342-07.*

FDA Label Image

Package Label-principal Display Panel (5 mg (100 Capsules Bottle))

This is a medication label for a bottle of Lenalidomide Capsules, containing 100 capsules of 5mg each. It warns that the drug has a potential for human birth defects and the dispenser should provide a medication guide to each patient. The prescribing information for dosing and administration is referenced on the label. There is also information on how to store the capsules, and where to print medication guides. The medication is distributed by Aurobindo Pharma and manufactured in India. The rest of the text shows technical printing information and should not be used for interpretation.*

FDA Label Image

Package Label-principal Display Panel (5 mg)

This is a package of Lenalidomide capsules distributed by Aurobindo Pharma USA, Inc. Each container includes 7 capsules of 5mg Lenalidomide. It is important to see the prescribing information before administering the capsules. The capsules should be stored at a controlled room temperature between 20°C and 25°C. The package carries a warning against possible birth defects and is not child-resistant. The package includes a note instructing pharmacists to dispense medication guides to patients separately. There is also a dotted line indicating an unvarnished area that should not be printed on the package.*

FDA Label Image

Package Label-principal Display Panel (10 mg (100 Capsules Bottle))

This is a medication description for Lenalidomide 10mg capsules, distributed by Aurobindo Pharma USA, Inc. The medication guide should be provided to patients by the pharmacist. The medication should be stored at controlled room temperature, and there is a warning about potential birth defects. The prescribing information should be checked for dosing and administration guidance. Printing the medication guide is available on www.aurobindousa.com.*

FDA Label Image

Chemical Structure (Lenalidomide Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.